Terapia de deprivación androgénica en cáncer de próstata avanzado. Estudio multicéntrico

Valencia-Guadalajara, Victor José; Martínez-Cayuelas, Laura; Sarrió-Sanz, Pau; Sánchez-Caballero, Laura; Polo-Hernández, Rebeca; Chillón-Sempere, Francisca Silvia; Galán-Llopis, Juan Antonio; Garcés-Valverde, Marina; Tenza-Tenza, José Antonio; Costa-Martínez, Asunción; García Serrado-Paumard, Diego; Escudero-Fontana, Eva; Tello-Royloa, Carlos; Patricia Verdú-Verdú, Lidia; Bravo-López, Diego Fernando; Pérez Seoane-Ballester, Helena; Pacheco-Bru, Juan José; Ortiz-Gorraiz, Manuel Ángel.
Arch. esp. urol. (Ed. impr.) ; 73(6): 499-508, jul.-ago. 2020. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-195925

Documentos relacionados

  1. [Androgen deprivation therapy in advanced prostate cancer. Multicenter study.]
  2. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
  3. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.
  4. Cytoreductive radical prostatectomy: who benefits from the surgical approach?
  5. Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer.
  6. Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data.
  7. [Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology].
  8. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
  9. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
  10. Multiparametric MRI-based 5-year Risk Prediction Model for Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy.